OBJECTIVES Atrial fibrillation (AF)/atrial flutter (AFL) during pregnancy in these women is associated with adverse outcome of pregnancy.
M
ajor cardiovascular adaptations occur in women during pregnancy (1) . Cardiac output increases 30% to 50% above baseline during normal pregnancy. In early pregnancy, increased cardiac output is primarily related to the rise in stroke volume. In late pregnancy, heart rate is the major factor (2) . Pregnancy is also a hypercoagulable state (3) . These physiological alterations have more of an impact in patients with pre-existing heart disease (4, 5) .
Arrhythmia, especially supraventricular tachycardia (SVT), is a known complication during pregnancy in patients with heart disease (6,7). The incidence of SVT seems to increase during pregnancy due to hemodynamic and maybe also hormonal changes, but evidence is scarce (8) . Atrial fibrillation (AF) is the most common clinically significant cardiac arrhythmia in the general population. Even though AF or atrial flutter (AFL) is rarely directly lifethreatening, each increases the risk of thromboembolism and may worsen cardiac function (9) (10) (11) .
Starting medical treatment for AF/AFL presents a difficult choice in practice, because most antiarrhythmic drugs can be regarded as potentially harmful to the fetus (6, 9) .
Current literature on the occurrence of arrhythmia during pregnancy and its effect in women with cardiac disease is limited. Therefore, we studied the incidence, onset, and predictors of AF/AFL in pregnant patients with heart disease, and we report on the maternal and fetal outcomes. In addition,
we present an overview of the current literature. pregnant patients with structural heart disease were enrolled. Nonstructural heart diseases, such as arrhythmias occurring in the context of a normal heart, were excluded.
METHODS
DATA. The study protocol and first results of this registry were published in 2013 (7) . Ischemic heart disease 1.9 0 1.9 1.00
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Values are mean AE SD or %.
AF ¼ atrial fibrillation; AFL ¼ atrial flutter; NYHA ¼ New York Heart Association. The number of patients per group is shown in parentheses. All cardiac includes CHD, VHD, CMP, and IHD. AF/AFL ¼ atrial fibrillation or flutter; CHD ¼ congenital heart disease; CMP ¼ cardiomyopathy; IHD ¼ ischemic heart disease; VHD ¼ valvular heart disease.
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AF or AFL During Pregnancy
Onset of AF/AFL was displayed as weeks of gestational age. Salam et al.
A U G U S T 2 0 1 5 : 2 8 4 -9 2 septal defects and ventricular septal defects). Fractional shortening <30% on echocardiography was also analyzed with the univariable logistic regression analysis.
STATISTICAL METHODS. Categorical data are presented as frequencies and percentages. Continuous data are presented as mean AE SD when considered normally distributed, as was checked using Kolmogorov-Smirnov tests. The chi-squared or Fisher exact tests were used to compare differences in categorical data between independent patient groups, whereas Student t test was used to compare differences in continuous data between independent patient groups. The intention was to adjust birth weight by a linear regression for multiple factors.
However, due to the small number of cases in the AF/AFL group, adjustment was only applied for gestational age. Baseline patient characteristics associated with AF/AFL were identified with univariable logistic regression analysis. Multivariable analysis was not done because of the small number of cases. A p value of <0.05 (2-sided test) was considered statistically significant. All statistical 
Salam et al. Table 1 .
Differences were found in underlying diagnoses. VHD was the most common underlying problem in patients with AF/AFL. No patients with ischemic heart disease developed AF/AFL. The incidence of AF/AFL within each cardiac diagnosis category is depicted in Figure 1 .
Detailed information on the patients with AF/AFL is provided in Table 2 .
PREDICTORS AND ONSET OF AF/AFL. The results of the univariable logistic regression are shown in Table 3 . It appeared that patients enrolled in centers with at least 1 AF/AFL event had different characteristics than the remaining patients did. Unfortunately, due to the low number of endpoint events, it was not possible to correct for the differences between the centers. Online Table 1 In all patients, AF/AFL occurred during pregnancy and once after delivery ( Figure 2) . Onset of AF/AFL was mainly at the end of the second trimester.
MEDICATION BEFORE AND DURING PREGNANCY.
During pregnancy, 14 patients (82%) used medication. Details concerning antiarrhythmic medication and anticoagulants are listed in Table 2 . weeks after the expulsion of the pregnancy due to sepsis, which was followed by the event of AF. Both patients did not suffer from heart failure prior to their demise.
There were no significant differences in cardiac and obstetric complications during pregnancy in the patients with versus without AF/AFL ( Table 4) . Hospitalization during pregnancy was needed for 12 patients (71%). All hospital admissions were for cardiac reasons.
Fetal outcome is summarized in Table 4 .
DISCUSSION
This is the first study to examine in detail the incidence, predictors, and outcomes of AF/AFL in pregnant patients with heart disease. In this large prospective international registry of 1,321 patients with heart disease, 1.3% experienced documented AF/AFL, which occurred most frequently at the end of the second trimester. Pre-pregnancy predictors of AF/AFL were AF before pregnancy, mitral valve disease, beta-blocker use, and left-sided lesions. AF/AFL was associated with higher rates of maternal mortality and lower fetal birth weight.
LITERATURE AND INCIDENCE OF AF/AFL. Existing data on the incidence of AF/AFL, during pregnancy in patients with heart disease is limited and based on small case series and individual case reports (Online Table 1 Salam et al.
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A U G U S T 2 0 1 5 : 2 8 4 -9 2 C o n g e n i t a l h e a r t d i s e a s e . We observed AF/AFL in 0.7% of CHD patients. There was 1 previous report (12) that assessed the progress and outcome of 482 pregnancies in 232 patients with CHD. AFL occurred in that study in 2 patients (0.4%). V a l v u l a r h e a r t d i s e a s e . AF/AFL occurred in 10 patients with mitral VHD (3%) in our study (7); 4 of them had valve surgery in the past. Available literature on AF/AFL in VHD and pregnancy is in the form of case series reports and incidence varies from 2% to 17.5% (13, 14, 16) .
We also collected the literature regarding AF/AFL in pregnancy in women without structural cardiac disease. This is summarized in Online Table 2 , which is available in the Online Appendix. In summary, these studies are mainly case reports of women experiencing AF during the third trimester, with good outcomes of both mother and fetus. MATERNAL AND FETAL OUTCOME. We report an increase in maternal deaths in cardiac patients with AF/AFL during or shortly after pregnancy (11.8%).
This is probably attributable partly to the severity of Table 1 .
FIGURE 2 Onset of AF/AFL During Pregnancy in Patients
With Heart Disease Exact timing of onset is missing in 4 patients. AF/AFL ¼ atrial fibrillation or flutter.
AF or AFL During Pregnancy the underlying cardiac condition and the thromboembolic risk might also play a role. As we report on 2 mortality cases only, a definitive conclusion on causative mechanisms cannot be drawn. Only 1 previous report (13) has described mortality in a patient due to heart failure.
We did not find any increase in fetal loss in women with AF/AFL. A low birth weight was more common in the offspring of patients with than those without AF/ AFL. Adjusted for pregnancy duration, the absolute birth weight remained remarkably lower in patients suffering AF/AFL during pregnancy. However, it was not appropriate to statistically correct for factors such as the use of beta-blockers during pregnancy and the type of underlying cardiac disease, which might influence the birth weight as well.
MANAGEMENT OF AF/AFL DURING PREGNANCY. In the management of patients with AF/AFL in pregnancy, several issues should be taken into consideration. First, the teratogenic potential of antiarrhythmic drugs limits the use of these agents during pregnancy. From many of these drugs, information on safety in pregnancy is lacking and most pharmaceutical companies advise not taking these drugs during pregnancy. Second, the hemodynamic alteration during pregnancy can alter the pharmacokinetics of the antiarrhythmic drugs. For instance, for digoxin, the dose needed for adequate serum levels during pregnancy is higher than for those outside pregnancy. In addition, anticoagulation needs consideration because pregnancy is a thrombogenic state (6) . However, bleeding complications are also more often encountered, in particular during delivery. Anticoagulants and beta-blockers constitute the medications of first choice in the management of patients with AF/AFL in pregnancy and both were used in twothirds of our patients. No increase in bleeding complication rates was observed in our patients on anticoagulants. Finally, electrical cardioversion is reported to be safe during pregnancy, but anesthetic management needs careful consideration in the pregnant woman. In our study, this was not reported.
To achieve a more definite management of the arrhythmia in case of poor tolerance and drug resistance, radiofrequency catheter ablation might be considered. Radiofrequency ablation for AF/AFL during pregnancy has not been reported to date.
There is limited evidence from case reports and series STUDY LIMITATIONS. As with all registries, there was some missing information, which comprised 4% in our registry. Some of the previously identified predictors (e.g., hypothyroidism and stress) were neither confirmed nor contradicted in this study, because these data were not collected. Although AF/AFL is an 
CONCLUSIONS
In this large prospective international registry of women with heart disease, the incidence of AF/AFL during pregnancy was 1.3% and occurred mainly at Netherlands. E-mail: j.roos@erasmusmc.nl.
PERSPECTIVES COMPETENCY IN MEDICAL KNOWLEDGE:
Although AF/ AFL during pregnancy has a low incidence rate of 1.3% in patients with structural heart disease, it is associated with an increased maternal mortality and low birth weight. With a peak in the second trimester, these patients should be routinely screened for this arrhythmia during that period and closely followed throughout pregnancy and delivery with a special focus on patients with history of AF/AFL before pregnancy, mitral valve disease, beta-blocker use, and left-sided lesions.
TRANSLATIONAL OUTLOOK: Further studies are warranted to examine the incidence and effects of asymptomatic AF/AFL occurring during pregnancy in patients with structural heart disease (using 24-h Holter or transtelephonic monitoring), particularly in the second trimester.
